Market research
135A.F SCYNEXIS, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 24.36
- Dividend yield
- Not available
- Beta
- 1.12
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US8112922005
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 24.36
- Dividend yield
- Not available
- Beta
- 1.12
About
About SCYNEXIS, Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 135A.F discussion.
5 years, 5 months ago
SCYNEXIS, Inc is currently in a long term uptrend where the price is trading 1.2% above its 200 day moving average.
From a valuation standpoint, the stock is 94.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 78.0.
SCYNEXIS, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 195.4% to $-43M since the same quarter in the previous year.
Finally, its free cash flow fell by 23.1% to $-17M since the same quarter in the previous year.
Based on the above factors, SCYNEXIS, Inc gets an overall score of 2/5.